Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | GABRE | P78334 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16054755 | 0.98 | GABRP (0.39) | GABRPGABRDGABRA1TSHRGABRB1 | |
| SCHEMBL659836 | 0.91 | MAPT (0.38) | GABRPGABRDGABRA1TSHRGABRB1 | |
| SCHEMBL690050 | 0.91 | MAPT (0.38) | GABRPGABRDGABRA1TSHRGABRB1 | |
| SCHEMBL661356 | 0.91 | MAPT (0.38) | GABRPGABRDGABRA1TSHRGABRB1 | |
| SCHEMBL2423420 | 0.90 | GABRP (0.38) | GABRPGABRDGABRA1TSHRGABRB1 | |
| SCHEMBL4438483 | 0.87 | GABRP (0.36) | GABRPGABRDGABRA1TSHRGABRB1 | |
| SCHEMBL1376080 | 0.86 | GABRP (0.41) | GABRPGABRDGABRA1TSHRGABRB1 | |
| SCHEMBL16051286 | 0.86 | GABRP (0.41) | GABRPGABRDGABRA1TSHRGABRB1 | |
| SCHEMBL28056841 | 0.86 | TSHR (0.41) | GABRPGABRDGABRA1TSHRGABRB1 | |
| SCHEMBL2461649 | 0.85 | CHRNB2 (0.36) | NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740955-A2 | NOVEL GLP-1 ANALOGUES | Sun Pharmaceutical Industries Limited (IN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4702020-A1 | PYRIDOIMIDAZOLONE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2026-03-04 | — | — | EP | disclosed |
| US-12421289-B2 | GLP-1 analogues | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2025-09-23 | — | — | US | disclosed |
| US-20240376175-A1 | Novel GLP-1 Analogues | SUN PHARMACEUTICAL IND LTD (IN) | 2024-11-14 | — | — | US | disclosed |
| WO-2024223905-A1 | PYRIDOIMIDAZOLONE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-10-31 | — | — | WO | disclosed |
| EP-4433471-A1 | N-(2H-INDAZOL-5-YL)PYRAZINE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS HTT MODULATORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE | CHDI Foundation, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240199718-A1 | GLP-1 Analogues | SUN PHARMACEUTICAL IND LTD (IN) | 2024-06-20 | — | — | US | disclosed |
| WO-2024097063-A1 | POLYMORPHIC FORMS OF A SOLUBLE EPOXIDE HYDROLASE INHIBITOR AND FORMULATIONS THEREOF | EICOSIS, LLC (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4364751-A2 | NOVEL GLP-1 ANALOGUES | Sun Pharmaceutical Industries Limited (IN) | 2024-05-08 | — | — | EP | disclosed |
| CN-117964735-A | Novel GLP-1 analogues | 太阳医药工业有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2001064679-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-07 | — | — | WO | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076971-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076972-A1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076512-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000059498-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1003514-A1 | CYCLIC AMINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| WO-1999004794-A1 | CYCLIC AMINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376175-A1 | Novel GLP-1 Analogues | GLP1R, GIPR, GPR119 | GABRP 417/4885GABRD 904/4885GABRA1 1243/4885 |
| US-12421289-B2 | GLP-1 analogues | GLP1R, GIPR, GPR119 | GABRP 308/4885GABRD 664/4885GABRA1 1106/4885 |
| US-20240199718-A1 | GLP-1 Analogues | GLP1R, GIPR, GPR119 | GABRP 308/4885GABRD 664/4885GABRA1 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.